Body size measures, hemostatic and inflammatory markers and risk of venous thrombosis: The Longitudinal Investigation of Thromboembolism Etiology.

Pubmed ID: 27328432

Pubmed Central ID: PMC4980192

Journal: Thrombosis research

Publication Date: Aug. 1, 2016

Affiliation: University of Minnesota, United States.

MeSH Terms: Humans, Male, Female, Aged, Risk Factors, Cohort Studies, Middle Aged, Follow-Up Studies, Obesity, Body Size, C-Reactive Protein, Inflammation, von Willebrand Factor, Waist-Hip Ratio, Hemostasis, Biomarkers, Venous Thrombosis, Factor VII, Fibrin Fibrinogen Degradation Products

Grants: N01 HC085086, R01 HL059367, N01 HC055019

Authors: Cushman M, Folsom AR, Heckbert SR, O'Meara ES, Zakai NA, Rosamond W

Cite As: Cushman M, O'Meara ES, Heckbert SR, Zakai NA, Rosamond W, Folsom AR. Body size measures, hemostatic and inflammatory markers and risk of venous thrombosis: The Longitudinal Investigation of Thromboembolism Etiology. Thromb Res 2016 Aug;144:127-32. Epub 2016 Jun 15.

Studies:

Abstract

OBJECTIVE: Obesity is an important venous thrombosis (VT) risk factor but the reasons for this are unclear. MATERIALS AND METHODS: In a cohort of 20,914 individuals aged 45 and older without prior VT, we calculated the relative risk (RR) of VT over 12.6years follow-up according to baseline body size measures, and studied whether associations were mediated by biomarkers of hemostasis and inflammation that are related to adiposity. RESULTS: Greater levels of all body size measures (weight, height, waist, hip circumference, calf circumference, body-mass index, waist-hip ratio, fat mass and fat-free mass) were associated with increased risk of VT, with 4th versus 1st quartile RRs of 1.5-3.0. There were no multiplicative interactions of biomarkers with obesity status. Adjustment for biomarkers associated with VT risk and body size (factors VII and VIII, von Willebrand factor, partial thromboplastin time, D-dimer, C-reactive protein and factor XI) only marginally lowered, or did not impact, the RRs associated with body size measures. CONCLUSIONS: Greater body size, by multiple measures, is a risk factor for VT. Associations were not mediated by circulating levels of studied biomarkers suggesting that body size relates to VT because of physical factors associated with blood flow, not the hypercoagulability or inflammation associated with adiposity.